25 XP   0   0   10

Vcanbio Cell & Gene Engineering Corp Ltd
Buy, Hold or Sell?

Let's analyse Vcanbio together

PenkeI guess you are interested in Vcanbio Cell & Gene Engineering Corp Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vcanbio Cell & Gene Engineering Corp Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vcanbio Cell & Gene Engineering Corp Ltd

I send you an email if I find something interesting about Vcanbio Cell & Gene Engineering Corp Ltd.

Quick analysis of Vcanbio (30 sec.)










What can you expect buying and holding a share of Vcanbio? (30 sec.)

How much money do you get?

How much money do you get?
¥0.00
When do you have the money?
1 year
How often do you get paid?
82.5%

What is your share worth?

Current worth
¥8.15
Expected worth in 1 year
¥8.55
How sure are you?
67.5%

+ What do you gain per year?

Total Gains per Share
¥0.40
Return On Investment
2.4%

For what price can you sell your share?

Current Price per Share
¥16.26
Expected price per share
¥12.88 - ¥17.65
How sure are you?
50%

1. Valuation of Vcanbio (5 min.)




Live pricePrice per Share (EOD)

¥16.26

Intrinsic Value Per Share

¥0.68 - ¥4.73

Total Value Per Share

¥8.83 - ¥12.88

2. Growth of Vcanbio (5 min.)




Is Vcanbio growing?

Current yearPrevious yearGrowGrow %
How rich?$528m$491.8m$24.4m4.7%

How much money is Vcanbio making?

Current yearPrevious yearGrowGrow %
Making money$4.5m$2.7m$1.7m39.6%
Net Profit Margin8.1%4.9%--

How much money comes from the company's main activities?

3. Financial Health of Vcanbio (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#106 / 1031

Most Revenue
#130 / 1031

Most Profit
#101 / 1031

Most Efficient
#134 / 1031

What can you expect buying and holding a share of Vcanbio? (5 min.)

Welcome investor! Vcanbio's management wants to use your money to grow the business. In return you get a share of Vcanbio.

What can you expect buying and holding a share of Vcanbio?

First you should know what it really means to hold a share of Vcanbio. And how you can make/lose money.

Speculation

The Price per Share of Vcanbio is ¥16.26. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vcanbio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vcanbio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥8.15. Based on the TTM, the Book Value Change Per Share is ¥0.10 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vcanbio.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.1%0.010.1%0.010.0%0.000.0%0.010.0%
Usd Book Value Change Per Share0.010.1%0.010.1%0.000.0%0.010.1%0.030.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.1%0.010.1%0.000.0%0.010.1%0.030.2%
Usd Price Per Share2.52-2.42-2.98-2.78-3.13-
Price to Earnings Ratio42.68-44.14-28.81-50.96-66.78-
Price-to-Total Gains Ratio218.84-252.39--25.84-74.64--138.12-
Price to Book Ratio2.23-2.20-2.84-2.67-6.23-
Price-to-Total Gains Ratio218.84-252.39--25.84-74.64--138.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.250384
Number of shares444
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.010.01
Gains per Quarter (444 shares)6.104.08
Gains per Year (444 shares)24.4016.32
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1024141156
20493823122
30736234638
41978636254
5112111047770
6114613459386
711701586108102
811941827124118
912182068139134
1012432309154150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%16.04.00.080.0%29.04.07.072.5%57.04.026.065.5%
Book Value Change Per Share4.00.00.0100.0%8.04.00.066.7%13.07.00.065.0%26.014.00.065.0%51.036.00.058.6%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%33.00.07.082.5%60.00.027.069.0%
Total Gains per Share4.00.00.0100.0%8.04.00.066.7%13.07.00.065.0%27.013.00.067.5%58.029.00.066.7%

Fundamentals of Vcanbio

About Vcanbio Cell & Gene Engineering Corp Ltd

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell detection tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, the company is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and synthetic agents; and in vitro diagnostic reagents and medical devices. The company was founded in 1992 and is based in Tianjin, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-03-26 19:05:08.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Vcanbio Cell & Gene Engineering Corp Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vcanbio earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Vcanbio to the Biotechnology industry mean.
  • A Net Profit Margin of 12.3% means that ¥0.12 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 12.3%. The company is making a huge profit. +2
  • The TTM is 8.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ12.3%TTM8.1%+4.2%
TTM8.1%YOY4.9%+3.3%
TTM8.1%5Y0.2%+8.0%
5Y0.2%10Y10.9%-10.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.3%-159.2%+171.5%
TTM8.1%-202.3%+210.4%
YOY4.9%-263.0%+267.9%
5Y0.2%-452.4%+452.6%
10Y10.9%-589.0%+599.9%
1.1.2. Return on Assets

Shows how efficient Vcanbio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vcanbio to the Biotechnology industry mean.
  • 0.9% Return on Assets means that Vcanbio generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.6%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.9%TTM0.6%+0.3%
TTM0.6%YOY0.4%+0.2%
TTM0.6%5Y0.0%+0.6%
5Y0.0%10Y0.8%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9%-12.5%+13.4%
TTM0.6%-12.2%+12.8%
YOY0.4%-11.2%+11.6%
5Y0.0%-13.3%+13.3%
10Y0.8%-14.6%+15.4%
1.1.3. Return on Equity

Shows how efficient Vcanbio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vcanbio to the Biotechnology industry mean.
  • 1.3% Return on Equity means Vcanbio generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM0.9%+0.5%
TTM0.9%YOY0.6%+0.3%
TTM0.9%5Y0.0%+0.9%
5Y0.0%10Y1.6%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3%-16.0%+17.3%
TTM0.9%-15.8%+16.7%
YOY0.6%-13.9%+14.5%
5Y0.0%-18.2%+18.2%
10Y1.6%-19.1%+20.7%

1.2. Operating Efficiency of Vcanbio Cell & Gene Engineering Corp Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vcanbio is operating .

  • Measures how much profit Vcanbio makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vcanbio to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.1%-3.1%
TTM3.1%YOY7.2%-4.2%
TTM3.1%5Y6.4%-3.3%
5Y6.4%10Y3.7%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM3.1%-208.5%+211.6%
YOY7.2%-280.2%+287.4%
5Y6.4%-459.9%+466.3%
10Y3.7%-596.9%+600.6%
1.2.2. Operating Ratio

Measures how efficient Vcanbio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.13 means that the operating costs are ¥1.13 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 1.131. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.200. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.131TTM1.200-0.069
TTM1.200YOY1.192+0.009
TTM1.2005Y1.219-0.018
5Y1.21910Y0.789+0.430
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1312.817-1.686
TTM1.2003.181-1.981
YOY1.1923.609-2.417
5Y1.2195.554-4.335
10Y0.7897.396-6.607

1.3. Liquidity of Vcanbio Cell & Gene Engineering Corp Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vcanbio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.72 means the company has ¥1.72 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 1.717. The company is able to pay all its short-term debts. +1
  • The TTM is 1.646. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.717TTM1.646+0.071
TTM1.646YOY1.506+0.140
TTM1.6465Y1.451+0.195
5Y1.45110Y0.771+0.680
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7173.987-2.270
TTM1.6464.440-2.794
YOY1.5065.569-4.063
5Y1.4516.158-4.707
10Y0.7716.492-5.721
1.3.2. Quick Ratio

Measures if Vcanbio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vcanbio to the Biotechnology industry mean.
  • A Quick Ratio of 0.41 means the company can pay off ¥0.41 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 0.406. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.394. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.406TTM0.394+0.012
TTM0.394YOY0.389+0.005
TTM0.3945Y0.442-0.049
5Y0.44210Y0.322+0.121
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4063.653-3.247
TTM0.3944.158-3.764
YOY0.3895.515-5.126
5Y0.4426.012-5.570
10Y0.3226.206-5.884

1.4. Solvency of Vcanbio Cell & Gene Engineering Corp Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vcanbio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vcanbio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30 means that Vcanbio assets are financed with 29.6% credit (debt) and the remaining percentage (100% - 29.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 0.296. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.301. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.296TTM0.301-0.004
TTM0.301YOY0.304-0.003
TTM0.3015Y0.298+0.003
5Y0.29810Y0.376-0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2960.336-0.040
TTM0.3010.330-0.029
YOY0.3040.267+0.037
5Y0.2980.367-0.069
10Y0.3760.378-0.002
1.4.2. Debt to Equity Ratio

Measures if Vcanbio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vcanbio to the Biotechnology industry mean.
  • A Debt to Equity ratio of 43.5% means that company has ¥0.43 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The MRQ is 0.435. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.443. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.435TTM0.443-0.009
TTM0.443YOY0.446-0.003
TTM0.4435Y0.439+0.004
5Y0.43910Y0.716-0.277
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4350.376+0.059
TTM0.4430.398+0.045
YOY0.4460.334+0.112
5Y0.4390.431+0.008
10Y0.7160.476+0.240

2. Market Valuation of Vcanbio Cell & Gene Engineering Corp Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Vcanbio generates.

  • Above 15 is considered overpriced but always compare Vcanbio to the Biotechnology industry mean.
  • A PE ratio of 42.68 means the investor is paying ¥42.68 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The EOD is 38.169. Based on the earnings, the company is overpriced. -1
  • The MRQ is 42.676. Based on the earnings, the company is overpriced. -1
  • The TTM is 44.144. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD38.169MRQ42.676-4.507
MRQ42.676TTM44.144-1.468
TTM44.144YOY28.815+15.329
TTM44.1445Y50.960-6.816
5Y50.96010Y66.782-15.822
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD38.169-2.697+40.866
MRQ42.676-2.422+45.098
TTM44.144-2.709+46.853
YOY28.815-4.116+32.931
5Y50.960-6.257+57.217
10Y66.782-6.478+73.260
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The EOD is 34.368. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 38.426. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 108.915. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD34.368MRQ38.426-4.058
MRQ38.426TTM108.915-70.488
TTM108.915YOY104.963+3.951
TTM108.9155Y62.822+46.093
5Y62.82210Y22.567+40.254
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD34.368-3.344+37.712
MRQ38.426-2.939+41.365
TTM108.915-3.486+112.401
YOY104.963-5.592+110.555
5Y62.822-8.464+71.286
10Y22.567-8.872+31.439
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vcanbio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.23 means the investor is paying ¥2.23 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Vcanbio Cell & Gene Engineering Corp Ltd:

  • The EOD is 1.994. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.230. Based on the equity, the company is underpriced. +1
  • The TTM is 2.197. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.994MRQ2.230-0.235
MRQ2.230TTM2.197+0.033
TTM2.197YOY2.843-0.646
TTM2.1975Y2.668-0.472
5Y2.66810Y6.230-3.561
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9942.198-0.204
MRQ2.2302.042+0.188
TTM2.1972.121+0.076
YOY2.8432.907-0.064
5Y2.6683.682-1.014
10Y6.2304.114+2.116
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Vcanbio Cell & Gene Engineering Corp Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0830.099-16%-0.030+137%0.063+31%0.188-56%
Book Value Per Share--8.1537.972+2%7.594+7%7.543+8%5.391+51%
Current Ratio--1.7171.646+4%1.506+14%1.451+18%0.771+123%
Debt To Asset Ratio--0.2960.301-1%0.304-2%0.2980%0.376-21%
Debt To Equity Ratio--0.4350.443-2%0.446-2%0.439-1%0.716-39%
Dividend Per Share--0.0000.001-14%0.001-36%0.004-87%0.006-92%
Eps--0.1070.099+7%0.042+152%0.011+866%0.053+101%
Free Cash Flow Per Share--0.1180.095+24%0.084+41%0.083+42%0.028+318%
Free Cash Flow To Equity Per Share--0.1180.105+13%0.057+106%0.108+10%0.150-21%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.825+21%
Intrinsic Value_10Y_max--4.727--------
Intrinsic Value_10Y_min--0.678--------
Intrinsic Value_1Y_max--0.409--------
Intrinsic Value_1Y_min--0.106--------
Intrinsic Value_3Y_max--1.278--------
Intrinsic Value_3Y_min--0.288--------
Intrinsic Value_5Y_max--2.206--------
Intrinsic Value_5Y_min--0.434--------
Market Cap7608850609.920-12%8507312674.5608192616977.440+4%10079621287.680-16%9397911860.557-9%10585754249.639-20%
Net Profit Margin--0.1230.081+51%0.049+152%0.002+7066%0.109+13%
Operating Margin---0.031-100%0.072-100%0.064-100%0.037-100%
Operating Ratio--1.1311.200-6%1.192-5%1.219-7%0.789+43%
Pb Ratio1.994-12%2.2302.197+2%2.843-22%2.668-16%6.230-64%
Pe Ratio38.169-12%42.67644.144-3%28.815+48%50.960-16%66.782-36%
Price Per Share16.260-12%18.18017.508+4%21.540-16%20.083-9%22.622-20%
Price To Free Cash Flow Ratio34.368-12%38.426108.915-65%104.963-63%62.822-39%22.567+70%
Price To Total Gains Ratio195.725-12%218.836252.395-13%-25.837+112%74.638+193%-138.123+163%
Quick Ratio--0.4060.394+3%0.389+4%0.442-8%0.322+26%
Return On Assets--0.0090.006+50%0.004+141%0.000+101%0.008+16%
Return On Equity--0.0130.009+50%0.006+139%0.000+103%0.016-13%
Total Gains Per Share--0.0830.099-16%-0.029+135%0.066+25%0.193-57%
Usd Book Value--528045145.851516288946.038+2%491841339.893+7%488516134.333+8%349175729.736+51%
Usd Book Value Change Per Share--0.0110.014-16%-0.004+137%0.009+31%0.026-56%
Usd Book Value Per Share--1.1281.103+2%1.051+7%1.044+8%0.746+51%
Usd Dividend Per Share--0.0000.000-14%0.000-36%0.000-87%0.001-92%
Usd Eps--0.0150.014+7%0.006+152%0.002+866%0.007+101%
Usd Free Cash Flow--7660202.2726182170.851+24%5443652.655+41%5385478.962+42%1647964.282+365%
Usd Free Cash Flow Per Share--0.0160.013+24%0.012+41%0.012+42%0.004+318%
Usd Free Cash Flow To Equity Per Share--0.0160.015+13%0.008+106%0.015+10%0.021-21%
Usd Market Cap1053064924.413-12%1177412074.1591133858189.678+4%1395019586.215-16%1300671001.501-9%1465068388.150-20%
Usd Price Per Share2.250-12%2.5162.423+4%2.981-16%2.779-9%3.131-20%
Usd Profit--6897439.4774530802.281+52%2735050.883+152%334548.386+1962%3235196.663+113%
Usd Revenue--55953534.60054703728.160+2%53690518.422+4%50844160.773+10%39163605.295+43%
Usd Total Gains Per Share--0.0110.014-16%-0.004+135%0.009+25%0.027-57%
 EOD+4 -4MRQTTM+25 -10YOY+28 -75Y+28 -710Y+21 -15

3.2. Fundamental Score

Let's check the fundamental score of Vcanbio Cell & Gene Engineering Corp Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1538.169
Price to Book Ratio (EOD)Between0-11.994
Net Profit Margin (MRQ)Greater than00.123
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.406
Current Ratio (MRQ)Greater than11.717
Debt to Asset Ratio (MRQ)Less than10.296
Debt to Equity Ratio (MRQ)Less than10.435
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.009
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Vcanbio Cell & Gene Engineering Corp Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.427
Ma 20Greater thanMa 5016.750
Ma 50Greater thanMa 10016.712
Ma 100Greater thanMa 20018.462
OpenGreater thanClose15.950
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Interest Income  7,82923,13130,959-26,1104,84911,37016,219-45,135-28,915



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets5,422,684
Total Liabilities1,607,329
Total Stockholder Equity3,699,101
 As reported
Total Liabilities 1,607,329
Total Stockholder Equity+ 3,699,101
Total Assets = 5,422,684

Assets

Total Assets5,422,684
Total Current Assets2,504,139
Long-term Assets2,918,545
Total Current Assets
Cash And Cash Equivalents 1,522,215
Net Receivables 591,659
Inventory 271,008
Other Current Assets 68,042
Total Current Assets  (as reported)2,504,139
Total Current Assets  (calculated)2,452,924
+/- 51,215
Long-term Assets
Property Plant Equipment 728,838
Goodwill 702,914
Intangible Assets 141,679
Long-term Assets Other 70,740
Long-term Assets  (as reported)2,918,545
Long-term Assets  (calculated)1,644,171
+/- 1,274,374

Liabilities & Shareholders' Equity

Total Current Liabilities1,458,579
Long-term Liabilities148,750
Total Stockholder Equity3,699,101
Total Current Liabilities
Accounts payable 109,217
Other Current Liabilities 56,430
Total Current Liabilities  (as reported)1,458,579
Total Current Liabilities  (calculated)165,648
+/- 1,292,932
Long-term Liabilities
Long term Debt 11,041
Capital Lease Obligations Min Short Term Debt81,520
Long-term Liabilities  (as reported)148,750
Long-term Liabilities  (calculated)92,560
+/- 56,189
Total Stockholder Equity
Total Stockholder Equity (as reported)3,699,101
Total Stockholder Equity (calculated)0
+/- 3,699,101
Other
Capital Stock467,949
Common Stock Shares Outstanding 467,949
Net Invested Capital 3,710,142
Net Working Capital 1,045,560
Property Plant and Equipment Gross 728,838



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-06-302000-12-312000-06-30
> Total Assets 
641,510
678,356
728,162
781,364
755,093
760,826
667,378
567,416
576,675
580,268
569,211
636,089
626,349
610,531
611,225
558,902
563,730
593,873
635,085
487,802
508,359
559,869
533,693
579,392
617,604
578,251
586,704
588,650
577,242
636,918
635,758
651,740
658,050
677,215
687,025
699,943
729,328
720,348
760,294
771,687
799,532
811,989
809,925
847,555
1,219,913
1,254,844
1,216,464
1,233,425
1,221,587
1,263,858
1,336,406
1,484,962
1,494,320
1,419,192
1,516,433
2,416,884
2,633,029
2,944,246
2,567,291
2,816,147
2,717,057
2,955,846
2,943,374
3,003,635
2,932,965
2,976,864
3,037,498
2,999,980
3,032,917
3,202,927
4,659,153
4,443,427
4,445,926
4,483,284
4,945,528
4,888,538
4,878,885
5,109,308
5,125,789
4,879,570
5,126,008
5,173,287
5,180,606
5,033,378
5,042,570
5,110,356
5,226,938
5,284,619
5,247,792
5,384,850
5,422,684
5,422,6845,384,8505,247,7925,284,6195,226,9385,110,3565,042,5705,033,3785,180,6065,173,2875,126,0084,879,5705,125,7895,109,3084,878,8854,888,5384,945,5284,483,2844,445,9264,443,4274,659,1533,202,9273,032,9172,999,9803,037,4982,976,8642,932,9653,003,6352,943,3742,955,8462,717,0572,816,1472,567,2912,944,2462,633,0292,416,8841,516,4331,419,1921,494,3201,484,9621,336,4061,263,8581,221,5871,233,4251,216,4641,254,8441,219,913847,555809,925811,989799,532771,687760,294720,348729,328699,943687,025677,215658,050651,740635,758636,918577,242588,650586,704578,251617,604579,392533,693559,869508,359487,802635,085593,873563,730558,902611,225610,531626,349636,089569,211580,268576,675567,416667,378760,826755,093781,364728,162678,356641,510
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
792,700
1,417,251
1,388,699
1,395,782
1,432,476
1,918,865
1,905,869
1,913,093
1,912,931
1,942,381
1,915,104
1,944,249
1,997,714
2,065,588
2,030,211
2,083,471
2,166,665
2,273,016
2,310,029
2,296,958
2,427,847
2,504,139
2,504,1392,427,8472,296,9582,310,0292,273,0162,166,6652,083,4712,030,2112,065,5881,997,7141,944,2491,915,1041,942,3811,912,9311,913,0931,905,8691,918,8651,432,4761,395,7821,388,6991,417,251792,700000000000000000000000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
257,212
528,418
585,243
473,753
553,737
990,676
631,693
700,892
697,717
1,010,204
1,060,319
1,039,946
1,107,763
1,176,969
1,195,655
1,190,854
1,260,667
1,323,545
1,393,432
1,381,339
1,475,495
1,522,215
1,522,2151,475,4951,381,3391,393,4321,323,5451,260,6671,190,8541,195,6551,176,9691,107,7631,039,9461,060,3191,010,204697,717700,892631,693990,676553,737473,753585,243528,418257,212000000000000000000000000000000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
401,669
300,673
300,524
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000300,524300,673401,669000000000000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
230,482
146,808
165,947
296,240
348,625
340,452
256,067
195,357
218,710
226,448
225,398
187,511
186,779
163,604
142,592
113,739
145,488
146,470
142,479
125,734
105,302
183,475
145,316
97,029
93,039
76,650
67,672
74,784
63,155
83,101
84,160
59,474
55,096
49,656
38,113
34,881
34,422
37,709
36,963
25,904
33,211
29,884
28,663
32,667
42,302
46,885
51,731
67,748
73,083
78,888
97,007
62,818
65,223
71,066
79,735
156,921
181,267
166,211
152,196
203,582
191,534
213,210
209,118
269,136
290,133
300,624
315,782
299,568
345,207
361,760
572,110
554,697
451,684
441,727
461,871
576,271
586,477
601,244
616,894
540,879
596,062
564,663
580,174
527,532
571,770
529,847
578,189
522,873
531,657
634,750
591,659
591,659634,750531,657522,873578,189529,847571,770527,532580,174564,663596,062540,879616,894601,244586,477576,271461,871441,727451,684554,697572,110361,760345,207299,568315,782300,624290,133269,136209,118213,210191,534203,582152,196166,211181,267156,92179,73571,06665,22362,81897,00778,88873,08367,74851,73146,88542,30232,66728,66329,88433,21125,90436,96337,70934,42234,88138,11349,65655,09659,47484,16083,10163,15574,78467,67276,65093,03997,029145,316183,475105,302125,734142,479146,470145,488113,739142,592163,604186,779187,511225,398226,448218,710195,357256,067340,452348,625296,240165,947146,808230,482
       Other Current Assets 
24,595
6,831
24,743
9,790
13,701
36,574
7,126
32,346
33,714
32,721
35,133
1,692
8,169
5,003
24,325
10,094
6,572
19,026
29,608
27,338
41,575
46,493
37,489
14,125
19,068
14,363
15,553
33,454
10,654
6,149
6,540
3,232
3,218
13,487
16,328
3,385
3,278
4,767
3,697
6,831
8,042
5,596
9,753
9,435
37,038
39,620
47,091
27,231
33,362
13,193
23,657
13,258
16,408
14,689
16,602
18,942
29,602
41,375
50,355
81,878
104,347
214,180
261,352
52,390
46,387
83,063
92,779
65,664
67,664
77,997
112,398
54,985
115,789
127,234
122,797
77,340
100,658
92,002
102,669
87,924
85,989
99,318
90,486
77,081
88,957
131,720
120,587
76,020
75,237
51,213
68,042
68,04251,21375,23776,020120,587131,72088,95777,08190,48699,31885,98987,924102,66992,002100,65877,340122,797127,234115,78954,985112,39877,99767,66465,66492,77983,06346,38752,390261,352214,180104,34781,87850,35541,37529,60218,94216,60214,68916,40813,25823,65713,19333,36227,23147,09139,62037,0389,4359,7535,5968,0426,8313,6974,7673,2783,38516,32813,4873,2183,2326,5406,14910,65433,45415,55314,36319,06814,12537,48946,49341,57527,33829,60819,0266,57210,09424,3255,0038,1691,69235,13332,72133,71432,3467,12636,57413,7019,79024,7436,83124,595
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,050,143
3,050,809
3,026,663
2,982,670
2,965,791
3,196,377
3,183,408
2,964,466
3,181,759
3,175,573
3,115,018
3,003,167
2,959,100
2,943,691
2,953,922
2,974,591
2,950,834
2,957,004
2,918,545
2,918,5452,957,0042,950,8342,974,5912,953,9222,943,6912,959,1003,003,1673,115,0183,175,5733,181,7592,964,4663,183,4083,196,3772,965,7912,982,6703,026,6633,050,8093,050,143000000000000000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
170,164
127,504
159,978
117,038
117,070
89,113
99,344
110,410
114,515
114,342
119,331
135,149
137,755
148,465
151,341
157,186
160,369
240,538
162,914
194,544
207,408
274,509
175,123
258,176
236,334
263,202
239,855
240,155
209,295
238,074
209,530
180,477
149,848
181,354
138,507
198,761
168,916
170,481
145,022
162,901
138,819
159,810
137,406
154,827
320,357
365,421
350,721
234,609
209,055
242,774
236,251
263,445
237,936
235,409
235,964
332,182
339,163
355,679
384,528
591,255
600,590
574,442
580,736
771,867
775,204
773,703
668,528
718,517
723,772
727,507
752,187
722,674
728,244
733,541
721,892
755,441
757,854
745,150
731,719
733,461
779,911
789,963
768,405
766,085
806,475
790,437
815,707
765,538
757,610
747,417
728,838
728,838747,417757,610765,538815,707790,437806,475766,085768,405789,963779,911733,461731,719745,150757,854755,441721,892733,541728,244722,674752,187727,507723,772718,517668,528773,703775,204771,867580,736574,442600,590591,255384,528355,679339,163332,182235,964235,409237,936263,445236,251242,774209,055234,609350,721365,421320,357154,827137,406159,810138,819162,901145,022170,481168,916198,761138,507181,354149,848180,477209,530238,074209,295240,155239,855263,202236,334258,176175,123274,509207,408194,544162,914240,538160,369157,186151,341148,465137,755135,149119,331114,342114,515110,41099,34489,113117,070117,038159,978127,504170,164
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,201
40,201
40,201
576,196
576,196
576,196
576,196
576,196
576,196
595,846
595,846
600,365
600,365
600,365
600,365
581,949
581,949
581,948
1,232,690
1,018,158
1,018,158
1,018,158
1,018,158
987,281
987,281
987,281
987,281
722,635
722,635
722,635
722,635
702,914
702,914
702,914
702,914
702,914
702,914
702,914
702,914
702,914702,914702,914702,914702,914702,914702,914702,914722,635722,635722,635722,635987,281987,281987,281987,2811,018,1581,018,1581,018,1581,018,1581,232,690581,948581,949581,949600,365600,365600,365600,365595,846595,846576,196576,196576,196576,196576,196576,19640,20140,20140,2010000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
558,627
567,978
562,089
556,712
613,258
605,541
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000605,541613,258556,712562,089567,978558,627000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
3,342
36,187
32,722
32,722
34,920
31,674
31,067
30,203
30,046
29,709
107,623
106,518
106,022
104,860
110,780
112,913
34,658
110,728
27,955
44,154
28,411
54,686
26,511
55,599
32,467
52,563
25,447
53,149
23,443
50,909
20,498
41,441
12,887
49,504
15,564
41,452
13,530
35,740
10,195
31,557
7,483
28,440
4,766
70,194
3,946
67,748
5,212
67,367
53,612
132,221
20,921
82,221
81,454
80,764
643,228
642,933
641,982
642,702
678,780
677,242
709,689
706,604
712,847
711,791
711,998
698,298
683,833
681,332
96,299
161,956
225,898
221,931
35,319
152,698
155,954
150,466
147,230
137,468
151,392
147,561
148,737
142,333
148,784
150,049
152,369
152,031
137,928
140,454
142,532
141,679
141,679142,532140,454137,928152,031152,369150,049148,784142,333148,737147,561151,392137,468147,230150,466155,954152,69835,319221,931225,898161,95696,299681,332683,833698,298711,998711,791712,847706,604709,689677,242678,780642,702641,982642,933643,22880,76481,45482,22120,921132,22153,61267,3675,21267,7483,94670,1944,76628,4407,48331,55710,19535,74013,53041,45215,56449,50412,88741,44120,49850,90923,44353,14925,44752,56332,46755,59926,51154,68628,41144,15427,955110,72834,658112,913110,780104,860106,022106,518107,62329,70930,04630,20331,06731,67434,92032,72232,72236,1873,3420
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
81,021
66,147
67,022
43,500
43,428
44,278
776,534
50,747
49,552
52,823
53,503
64,390
62,325
64,712
65,027
75,048
70,174
65,794
70,740
70,74065,79470,17475,04865,02764,71262,32564,39053,50352,82349,55250,747776,53444,27843,42843,50067,02266,14781,021000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
223,728
244,406
252,897
367,308
340,037
341,527
246,555
209,591
225,501
218,026
205,675
271,069
269,800
262,127
265,345
248,953
254,389
285,278
18,777
322,849
331,877
349,114
318,349
395,349
428,035
393,376
382,339
403,229
395,699
413,980
383,826
395,427
414,629
428,862
403,510
460,709
484,280
492,823
522,412
527,559
545,788
561,794
545,314
578,701
900,187
940,004
923,824
951,883
945,647
997,121
1,033,676
824,894
825,907
860,010
873,578
1,260,588
1,049,264
1,220,427
1,037,425
1,134,367
1,074,173
1,252,170
1,245,700
1,251,829
1,275,688
1,360,043
1,423,322
1,365,553
1,329,098
1,335,608
1,432,049
1,459,016
1,430,023
1,487,028
1,467,716
1,427,816
1,405,833
1,402,797
1,400,242
1,377,192
1,424,710
1,446,097
1,493,582
1,500,617
1,553,207
1,547,943
1,596,407
1,630,965
1,571,851
1,608,155
1,607,329
1,607,3291,608,1551,571,8511,630,9651,596,4071,547,9431,553,2071,500,6171,493,5821,446,0971,424,7101,377,1921,400,2421,402,7971,405,8331,427,8161,467,7161,487,0281,430,0231,459,0161,432,0491,335,6081,329,0981,365,5531,423,3221,360,0431,275,6881,251,8291,245,7001,252,1701,074,1731,134,3671,037,4251,220,4271,049,2641,260,588873,578860,010825,907824,8941,033,676997,121945,647951,883923,824940,004900,187578,701545,314561,794545,788527,559522,412492,823484,280460,709403,510428,862414,629395,427383,826413,980395,699403,229382,339393,376428,035395,349318,349349,114331,877322,84918,777285,278254,389248,953265,345262,127269,800271,069205,675218,026225,501209,591246,555341,527340,037367,308252,897244,406223,728
   > Total Current Liabilities 
223,729
245,670
249,161
313,572
286,301
287,791
242,819
204,455
220,364
212,890
200,539
265,982
264,918
256,975
260,664
244,645
243,613
274,502
300,175
305,742
315,665
332,906
300,911
382,311
413,899
386,355
375,279
362,362
355,297
410,103
383,827
391,990
411,408
424,782
400,249
457,768
481,349
489,939
519,643
525,944
544,136
560,343
544,314
575,335
895,911
935,917
920,602
949,076
943,031
994,694
1,030,802
821,973
823,177
857,469
870,848
1,204,027
991,844
1,160,021
982,745
1,059,060
1,016,853
1,131,540
1,133,101
1,149,326
1,179,780
1,181,767
1,202,019
1,171,462
1,144,679
1,160,500
1,246,233
1,267,522
1,257,295
1,318,931
1,310,716
1,350,003
1,330,680
1,329,996
1,329,843
1,300,015
1,324,844
1,357,354
1,382,441
1,395,647
1,422,620
1,415,376
1,442,879
1,471,495
1,412,669
1,453,041
1,458,579
1,458,5791,453,0411,412,6691,471,4951,442,8791,415,3761,422,6201,395,6471,382,4411,357,3541,324,8441,300,0151,329,8431,329,9961,330,6801,350,0031,310,7161,318,9311,257,2951,267,5221,246,2331,160,5001,144,6791,171,4621,202,0191,181,7671,179,7801,149,3261,133,1011,131,5401,016,8531,059,060982,7451,160,021991,8441,204,027870,848857,469823,177821,9731,030,802994,694943,031949,076920,602935,917895,911575,335544,314560,343544,136525,944519,643489,939481,349457,768400,249424,782411,408391,990383,827410,103355,297362,362375,279386,355413,899382,311300,911332,906315,665305,742300,175274,502243,613244,645260,664256,975264,918265,982200,539212,890220,364204,455242,819287,791286,301313,572249,161245,670223,729
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,809
0
20,476
49,934
49,934
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000049,93449,93420,476018,809000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,809
0
20,476
49,934
49,934
0
0
0
13,202
12,716
0
0
0
0
0
0
0
0
0
0
0
0
00000000000012,71613,20200049,93449,93420,476018,809000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
15,499
31,948
34,616
52,009
51,932
56,767
42,381
31,418
38,857
22,124
24,851
23,495
19,580
27,749
15,822
19,406
15,751
20,406
18,355
15,246
14,512
17,093
16,979
20,435
26,168
28,767
22,701
28,286
22,486
26,090
23,641
23,020
21,119
18,683
14,059
11,268
7,435
4,398
5,455
6,284
7,375
6,105
5,470
6,379
32,968
39,347
38,160
32,984
10,375
54,417
53,266
21,025
13,284
12,276
10,146
21,814
20,666
11,566
21,609
22,619
41,562
26,477
28,221
27,134
37,253
30,385
59,917
24,630
51,997
49,456
62,563
25,546
66,203
89,602
85,394
39,209
86,178
62,299
72,297
43,213
80,921
43,138
76,182
31,758
73,209
92,707
87,529
105,146
86,813
67,447
109,217
109,21767,44786,813105,14687,52992,70773,20931,75876,18243,13880,92143,21372,29762,29986,17839,20985,39489,60266,20325,54662,56349,45651,99724,63059,91730,38537,25327,13428,22126,47741,56222,61921,60911,56620,66621,81410,14612,27613,28421,02553,26654,41710,37532,98438,16039,34732,9686,3795,4706,1057,3756,2845,4554,3987,43511,26814,05918,68321,11923,02023,64126,09022,48628,28622,70128,76726,16820,43516,97917,09314,51215,24618,35520,40615,75119,40615,82227,74919,58023,49524,85122,12438,85731,41842,38156,76751,93252,00934,61631,94815,499
       Other Current Liabilities 
90,850
66,522
81,215
63,163
60,969
86,969
112,883
75,707
77,677
87,606
88,028
131,977
126,528
124,546
133,242
125,639
138,168
150,187
179,191
225,576
227,333
250,893
251,932
300,676
317,451
303,588
337,978
327,076
325,811
377,013
354,186
362,970
383,489
399,499
379,590
440,700
467,614
485,541
514,188
519,660
536,761
554,238
538,844
568,956
797,943
846,570
882,442
916,092
932,656
940,277
977,536
800,948
809,894
845,193
860,702
1,182,213
971,178
970,644
961,137
1,023,941
962,790
1,091,857
1,091,868
1,083,051
1,092,121
1,109,410
1,098,692
1,128,024
1,092,682
1,053,853
1,156,157
1,072,794
28,482
30,321
23,809
1,123,920
1,124,289
1,149,486
1,184,376
1,127,248
1,155,724
1,173,189
1,208,420
1,208,192
1,272,709
1,258,449
1,273,939
50,640
52,370
1,240,046
56,430
56,4301,240,04652,37050,6401,273,9391,258,4491,272,7091,208,1921,208,4201,173,1891,155,7241,127,2481,184,3761,149,4861,124,2891,123,92023,80930,32128,4821,072,7941,156,1571,053,8531,092,6821,128,0241,098,6921,109,4101,092,1211,083,0511,091,8681,091,857962,7901,023,941961,137970,644971,1781,182,213860,702845,193809,894800,948977,536940,277932,656916,092882,442846,570797,943568,956538,844554,238536,761519,660514,188485,541467,614440,700379,590399,499383,489362,970354,186377,013325,811327,076337,978303,588317,451300,676251,932250,893227,333225,576179,191150,187138,168125,639133,242124,546126,528131,97788,02887,60677,67775,707112,88386,96960,96963,16381,21566,52290,850
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
172,728
168,098
157,000
77,813
75,153
72,800
70,398
77,176
99,867
88,743
111,141
104,971
130,587
132,567
153,528
159,470
159,182
155,114
148,750
148,750155,114159,182159,470153,528132,567130,587104,971111,14188,74399,86777,17670,39872,80075,15377,813157,000168,098172,728000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
1,400
1,401
1,400
1,400
1,351
1,146
1,313
842
572
40
40
0
1,371
422
472
1,702
2,302
2,402
1,812
1,851
40,867
40,402
0
0
3,416
3,200
3,796
3,240
2,941
2,931
2,884
2,769
1,600
1,400
1,199
1,000
3,366
4,276
4,087
3,222
2,807
2,616
2,427
2,874
2,921
2,730
2,540
2,730
53,865
54,724
57,710
51,984
22,986
23,482
23,178
22,974
21,606
21,311
21,731
71,893
51,049
48,511
44,362
63,731
72,652
53,886
51,756
43,723
31,513
30,431
41,255
28,831
28,042
26,654
37,543
48,301
45,776
45,112
57,516
58,303
0
0
45,507
0
045,5070058,30357,51645,11245,77648,30137,54326,65428,04228,83141,25530,43131,51343,72351,75653,88672,65263,73144,36248,51151,04971,89321,73121,31121,60622,97423,17823,48222,98651,98457,71054,72453,8652,7302,5402,7302,9212,8742,4272,6162,8073,2224,0874,2763,3661,0001,1991,4001,6002,7692,8842,9312,9413,2403,7963,2003,4160040,40240,8671,8511,8122,4022,3021,7024724221,371040405728421,3131,1461,3511,4001,4001,4011,4000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
112,866
113,446
113,128
112,359
109,968
109,152
115,788
111,235
115,739
113,798
130,626
131,977
128,327
127,913
141,128
139,055
144,263
141,930
0
0
153,606
0
0153,60600141,930144,263139,055141,128127,913128,327131,977130,626113,798115,739111,235115,788109,152109,968112,359113,128113,446112,866000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
399,787
418,139
416,627
360,545
361,206
364,933
365,958
302,215
296,357
305,099
305,219
301,939
296,419
286,662
282,132
224,926
219,970
214,185
519,819
64,224
65,220
96,882
99,425
76,295
73,183
74,569
82,922
86,828
86,572
106,482
123,708
125,925
125,651
128,937
154,194
128,050
130,109
122,174
129,762
132,535
136,435
142,883
149,267
155,961
159,995
170,215
153,677
146,536
138,898
143,919
147,720
501,504
509,975
444,624
522,525
1,032,461
1,457,083
1,595,879
1,400,023
1,553,463
1,510,592
1,554,625
1,544,082
1,587,830
1,529,634
1,502,721
1,486,753
1,509,015
1,576,279
1,734,437
3,010,339
2,772,550
2,796,996
2,871,221
3,350,953
3,353,702
3,366,260
3,590,897
3,614,431
3,396,349
3,595,012
3,625,675
3,586,855
3,463,454
3,420,834
3,477,790
3,546,014
3,555,802
3,577,206
3,658,851
3,699,101
3,699,1013,658,8513,577,2063,555,8023,546,0143,477,7903,420,8343,463,4543,586,8553,625,6753,595,0123,396,3493,614,4313,590,8973,366,2603,353,7023,350,9532,871,2212,796,9962,772,5503,010,3391,734,4371,576,2791,509,0151,486,7531,502,7211,529,6341,587,8301,544,0821,554,6251,510,5921,553,4631,400,0231,595,8791,457,0831,032,461522,525444,624509,975501,504147,720143,919138,898146,536153,677170,215159,995155,961149,267142,883136,435132,535129,762122,174130,109128,050154,194128,937125,651125,925123,708106,48286,57286,82882,92274,56973,18376,29599,42596,88265,22064,224519,819214,185219,970224,926282,132286,662296,419301,939305,219305,099296,357302,215365,958364,933361,206360,545416,627418,139399,787
   Common Stock
156,267
156,267
156,267
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
250,028
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
325,041
349,291
349,291
349,291
352,541
375,398
386,255
386,255
386,255
386,255
386,255
386,091
386,091
386,091
386,091
386,091
386,081
385,213
384,219
383,981
440,161
440,161
440,161
440,161
467,977
467,970
467,970
467,970
467,970
467,949
467,949
467,949
467,949
467,949
467,949
467,949
467,949
0
0
467,949
0
0467,94900467,949467,949467,949467,949467,949467,949467,949467,949467,970467,970467,970467,970467,977440,161440,161440,161440,161383,981384,219385,213386,081386,091386,091386,091386,091386,091386,255386,255386,255386,255386,255375,398352,541349,291349,291349,291325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041325,041250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028250,028156,267156,267156,267
   Retained Earnings 
21,884
39,907
39,394
0
769
1,193
2,236
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,881
152,784
0
72,528
66,343
88,524
78,054
110,388
138,069
118,776
113,479
91,929
205,464
362,136
-355,920
-608,057
-600,371
-568,083
-537,712
-560,831
-554,714
-479,503
-427,729
-687,696
-642,142
-576,992
-496,873
-513,714
-477,890
-448,882
-399,164
-423,885
-386,511
-318,053
-291,373
-291,373-318,053-386,511-423,885-399,164-448,882-477,890-513,714-496,873-576,992-642,142-687,696-427,729-479,503-554,714-560,831-537,712-568,083-600,371-608,057-355,920362,136205,46491,929113,479118,776138,069110,38878,05488,52466,34372,5280152,78424,88100000000000000000000000000000000000000000000000002,2361,193769039,39439,90721,884
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000-28-28-279-1,260-2,128-2,138-2,138-2,138-2,302-2,302-2,302-2,30200000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-30
38,624
12,559
6,161
12,885
17,652
46,068
52,508
224,884
196,643
238,528
391,638
349,502
230,563
125,980
47,536
75,484
93,989
0
0
128,831
0
0128,8310093,98975,48447,536125,980230,563349,502391,638238,528196,643224,88452,50846,06817,65212,8856,16112,55938,624-30000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,581,033
Cost of Revenue-508,337
Gross Profit1,072,6951,072,695
 
Operating Income (+$)
Gross Profit1,072,695
Operating Expense-1,386,370
Operating Income194,663-313,675
 
Operating Expense (+$)
Research Development155,317
Selling General Administrative473,618
Selling And Marketing Expenses-
Operating Expense1,386,370628,934
 
Net Interest Income (+$)
Interest Income13,414
Interest Expense-397
Other Finance Cost-5,598
Net Interest Income18,615
 
Pretax Income (+$)
Operating Income194,663
Net Interest Income18,615
Other Non-Operating Income Expenses-
Income Before Tax (EBT)173,188194,663
EBIT - interestExpense = -397
130,948
131,345
Interest Expense397
Earnings Before Interest and Taxes (EBIT)-173,584
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax173,188
Tax Provision-50,603
Net Income From Continuing Ops122,585122,585
Net Income130,948
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--18,615
 

Technical Analysis of Vcanbio
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vcanbio. The general trend of Vcanbio is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vcanbio's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vcanbio Cell & Gene Engineering Corp Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 16.15 < 17.65 < 17.65.

The bearish price targets are: 12.88.

Tweet this
Vcanbio Cell & Gene Engineering Corp Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vcanbio Cell & Gene Engineering Corp Ltd. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vcanbio Cell & Gene Engineering Corp Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vcanbio Cell & Gene Engineering Corp Ltd. The current macd is -0.0748777.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vcanbio price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Vcanbio. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Vcanbio price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Vcanbio Cell & Gene Engineering Corp Ltd Daily Moving Average Convergence/Divergence (MACD) ChartVcanbio Cell & Gene Engineering Corp Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vcanbio Cell & Gene Engineering Corp Ltd. The current adx is 18.51.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Vcanbio shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Vcanbio Cell & Gene Engineering Corp Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vcanbio Cell & Gene Engineering Corp Ltd. The current sar is 17.38.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vcanbio Cell & Gene Engineering Corp Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vcanbio Cell & Gene Engineering Corp Ltd. The current rsi is 43.43. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Vcanbio Cell & Gene Engineering Corp Ltd Daily Relative Strength Index (RSI) ChartVcanbio Cell & Gene Engineering Corp Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vcanbio Cell & Gene Engineering Corp Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vcanbio price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Vcanbio Cell & Gene Engineering Corp Ltd Daily Stochastic Oscillator ChartVcanbio Cell & Gene Engineering Corp Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vcanbio Cell & Gene Engineering Corp Ltd. The current cci is -118.8913202.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Vcanbio Cell & Gene Engineering Corp Ltd Daily Commodity Channel Index (CCI) ChartVcanbio Cell & Gene Engineering Corp Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vcanbio Cell & Gene Engineering Corp Ltd. The current cmo is -20.03700825.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vcanbio Cell & Gene Engineering Corp Ltd Daily Chande Momentum Oscillator (CMO) ChartVcanbio Cell & Gene Engineering Corp Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vcanbio Cell & Gene Engineering Corp Ltd. The current willr is -79.42857143.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vcanbio is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Vcanbio Cell & Gene Engineering Corp Ltd Daily Williams %R ChartVcanbio Cell & Gene Engineering Corp Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vcanbio Cell & Gene Engineering Corp Ltd.

Vcanbio Cell & Gene Engineering Corp Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vcanbio Cell & Gene Engineering Corp Ltd. The current atr is 0.52473635.

Vcanbio Cell & Gene Engineering Corp Ltd Daily Average True Range (ATR) ChartVcanbio Cell & Gene Engineering Corp Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vcanbio Cell & Gene Engineering Corp Ltd. The current obv is 210,363,928.

Vcanbio Cell & Gene Engineering Corp Ltd Daily On-Balance Volume (OBV) ChartVcanbio Cell & Gene Engineering Corp Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vcanbio Cell & Gene Engineering Corp Ltd. The current mfi is 55.47.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Vcanbio Cell & Gene Engineering Corp Ltd Daily Money Flow Index (MFI) ChartVcanbio Cell & Gene Engineering Corp Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vcanbio Cell & Gene Engineering Corp Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-02STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-25STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Vcanbio Cell & Gene Engineering Corp Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vcanbio Cell & Gene Engineering Corp Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.427
Ma 20Greater thanMa 5016.750
Ma 50Greater thanMa 10016.712
Ma 100Greater thanMa 20018.462
OpenGreater thanClose15.950
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Vcanbio with someone you think should read this too:
  • Are you bullish or bearish on Vcanbio? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vcanbio? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vcanbio Cell & Gene Engineering Corp Ltd

I send you an email if I find something interesting about Vcanbio Cell & Gene Engineering Corp Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Vcanbio Cell & Gene Engineering Corp Ltd.

Receive notifications about Vcanbio Cell & Gene Engineering Corp Ltd in your mailbox!